Journal article
CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis
Cancer immunology, immunotherapy : CII, Vol.62(9), pp.1475-1484
09/2013
DOI: 10.1007/s00262-013-1452-4
PMCID: PMC3758443
PMID: 23812490
Abstract
CXCR5 [chemokine (C-X-C motif) receptor 5; also known as Burkitt lymphoma receptor 1 (BCR1)] is expressed on mature B-cells, subsets of CD4
+
and CD8
+
T-cells, and skin-derived migratory dendritic cells. Together with its ligand, CXCL13, CXCR5 is involved in guiding B-cells into the B-cell zones of secondary lymphoid organs as well as T-cell migration. This study evaluated the role of common germline genetic variation in
CXCR5
in the risk and prognosis of non-Hodgkin lymphoma (NHL) using a clinic-based study of 1521 controls and 2694 NHL cases including 710 chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL), 586 diffuse large B-cell lymphoma (DLBCL), 588 follicular lymphoma (FL), 137 mantle cell lymphoma (MCL), 230 marginal zone lymphoma (MZL) and 158 peripheral T-cell lymphoma (PTCL). Of the ten
CXCR5
tag SNPs in our study, five were associated with risk of NHL, with rs1790192 having the strongest association (OR=1.19, 95%CI 1.08–1.30; p=0.0003). This SNP was most strongly associated with the risk of FL (OR=1.44, 95%CI 1.25–1.66; p=3.1×10
−7
), with a lower degree of association with DLBCL (OR=1.16, 95%CI 1.01–1.33; p=0.04) and PTCL (OR=1.29, 95%CI 1.02–1.64; p=0.04) but no association with the risk of MCL or MZL. For FL patients that were observed as initial disease management, the number of minor alleles of rs1790192 was associated with better event-free survival (EFS) (HR=0.64; 95%CI 0.47–0.87; p=0.004). These results provide additional evidence for a role of host genetic variation in
CXCR5
in lymphomagenesis, particularly for FL.
Details
- Title: Subtitle
- CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis
- Creators
- Bridget Charbonneau - Department of Health Sciences Research, College of Medicine Mayo Clinic, 200 First Street SW, Rochester, MN, USABrian K Link - Division of Hematology, Oncology, and Blood & Marrow Transplantation Department of Internal Medicine, College of Medicine, University of Iowa, Iowa City, IA, USAAlice H Wang - Department of Health Sciences Research, College of Medicine Mayo Clinic, 200 First Street SW, Rochester, MN, USAGeorge J Weiner - Division of Hematology, Oncology, and Blood & Marrow Transplantation Department of Internal Medicine, College of Medicine, University of Iowa, Iowa City, IA, USAMatthew J Maurer - Department of Health Sciences Research, College of Medicine Mayo Clinic, 200 First Street SW, Rochester, MN, USAJames R Cerhan - Department of Health Sciences Research, College of Medicine Mayo Clinic, 200 First Street SW, Rochester, MN, USAYan W Asmann - Department of Health Sciences Research, College of Medicine Mayo Clinic, 200 First Street SW, Rochester, MN, USAClive S Zent - Department of Internal Medicine, Division of Hematology, College of Medicine Mayo Clinic, 200 First Street SW, Rochester, MN, USAStephen M Ansell - Department of Internal Medicine, Division of Hematology, College of Medicine Mayo Clinic, 200 First Street SW, Rochester, MN, USANazan Ozsan - Department of Pathology, Ege University Faculty of Medicine, Bornova, İzmir, TURAndrew L Feldman - Department of Laboratory Medicine and Pathology, College of Medicine Mayo Clinic, 200 First Street SW, Rochester, MN, USAThomas E Witzig - Department of Internal Medicine, Division of Hematology, College of Medicine Mayo Clinic, 200 First Street SW, Rochester, MN, USAJulie M Cunningham - Department of Laboratory Medicine and Pathology, College of Medicine Mayo Clinic, 200 First Street SW, Rochester, MN, USAAhmet Dogan - Department of Laboratory Medicine and Pathology, College of Medicine Mayo Clinic, 200 First Street SW, Rochester, MN, USAThomas M Habermann - Department of Internal Medicine, Division of Hematology, College of Medicine Mayo Clinic, 200 First Street SW, Rochester, MN, USASusan L Slager - Department of Health Sciences Research, College of Medicine Mayo Clinic, 200 First Street SW, Rochester, MN, USAAnne J Novak - Department of Internal Medicine, Division of Hematology, College of Medicine Mayo Clinic, 200 First Street SW, Rochester, MN, USA
- Resource Type
- Journal article
- Publication Details
- Cancer immunology, immunotherapy : CII, Vol.62(9), pp.1475-1484
- DOI
- 10.1007/s00262-013-1452-4
- PMID
- 23812490
- PMCID
- PMC3758443
- ISSN
- 0340-7004
- eISSN
- 1432-0851
- Grant note
- R01 CA129539 || CA / National Cancer Institute : NCI R01 CA092153 || CA / National Cancer Institute : NCI R25 CA092049 || CA / National Cancer Institute : NCI P50 CA097274 || CA / National Cancer Institute : NCI
- Language
- English
- Date published
- 09/2013
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Pharmaceutical Sciences and Experimental Therapeutics; Internal Medicine
- Record Identifier
- 9984094340302771
Metrics
13 Record Views